Baltimore, Maryland 21231


This Phase 1 clinical study is designed to examine the safety and feasibility of using anti-CD3/CD28 activated marrow infiltrating lymphocytes (MILs) as treatment of relapse after allogeneic hematopoietic cell transplantation (alloHCT) for patients with hematologic malignancies with bone marrow involvement of their relapsed disease. These MILs will be derived from the bone marrow of the relapsed patient who had previously received post-transplantation cyclophosphamide (PTCy) as graft-versus-host disease (GVHD) prophylaxis (PTCy-MILs). A bone marrow aspiration will be performed on the patient to collect ~200ml of marrow for ex vivo expansion. During this expansion process, T cells will be activated and expanded by co-stimulation with anti-CD3/anti-CD28 monoclonal antibodies covalently attached to super-paramagnetic microbeads. Patients will be treated with salvage therapy while this ex vivo expansion is ongoing. After the simultaneous salvage therapy and ex vivo expansion, the activated PTCy-MILs will be reinfused. Patients will be monitored with the primary objective being the feasibility of expanding to targeted dose levels activated PTCy-MILs that do not cause grade III-IV acute GVHD within the first 90 days after PTCy-MIL infusion.


Inclusion Criteria: - Age ≥18 years old - Bone marrow relapse of a hematologic malignancy ≥6 months after alloHCT using PTCy - Donor CD3+ chimerism ≥ 30% measured in peripheral blood or bone marrow - ECOG performance status ≤ 2 or Karnofsky performance scale ≥ 70%. - Off all immunosuppressive drugs for 2 weeks prior to the PTCy-MILs collection. - Expectation of ability to safely undergo salvage treatment appropriate for the patient's malignant disease type as determined by the treating hematologist/ oncologist. Exclusion Criteria: - Most recent alloHCT not utilizing PTCy. - Active GVHD requiring treatment. - Immunosuppression use within 28 days of PTCy-MIL infusion if prior grade II-IV acute GVHD. - Creatinine ≥ 2.5, total bilirubin > 3 times the upper limit of normal (ULN), or AST/ALT > 3 times the ULN. - HIV-1/2 or HTLV-1/2 positivity. - Life expectancy ≤ 90 days even with aggressive treatment, as determined by the treating hematologist/oncologist, which would preclude assessment of toxicity of PTCy-MILs



Primary Contact:

Principal Investigator
Leo Luznik, MD
Sidney Kimmel Cancer Center at Johns Hopkins

Leo Luznik, MD
Phone: 410-502-7732

Backup Contact:


Location Contact:

Baltimore, Maryland 21231
United States

Leo Luznik, M.D.
Phone: 410-502-3809

Site Status: Recruiting

Data Source:

Date Processed: March 16, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.